MA43601A1 - Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide - Google Patents

Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Info

Publication number
MA43601A1
MA43601A1 MA43601A MA43601A MA43601A1 MA 43601 A1 MA43601 A1 MA 43601A1 MA 43601 A MA43601 A MA 43601A MA 43601 A MA43601 A MA 43601A MA 43601 A1 MA43601 A1 MA 43601A1
Authority
MA
Morocco
Prior art keywords
hydroxypyrrolidine
pyrazolo
difluorophenyl
pyrrolidin
pyrimidin
Prior art date
Application number
MA43601A
Other languages
English (en)
Other versions
MA43601B1 (fr
Inventor
Mark Reynolds
Steven A Smith
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Priority claimed from PCT/US2017/025939 external-priority patent/WO2017176751A1/fr
Publication of MA43601A1 publication Critical patent/MA43601A1/fr
Publication of MA43601B1 publication Critical patent/MA43601B1/fr

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une formulation liquide de (s)-n-(5-((r)-2-(2,5-difluorophényl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, des sels pharmaceutiquement acceptables de celui-ci ou une combinaison de ceux-ci et l'utilisation de la formulation liquide dans le traitement de la douleur, du cancer, de l'inflammation et de certaines maladies infectieuses.
MA43601A 2016-04-04 2017-04-04 Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide MA43601B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662318041P 2016-04-04 2016-04-04
PCT/US2017/025939 WO2017176751A1 (fr) 2016-04-04 2017-04-04 Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Publications (2)

Publication Number Publication Date
MA43601A1 true MA43601A1 (fr) 2019-03-29
MA43601B1 MA43601B1 (fr) 2020-05-29

Family

ID=63036888

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43601A MA43601B1 (fr) 2016-04-04 2017-04-04 Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Country Status (2)

Country Link
AR (1) AR108090A1 (fr)
MA (1) MA43601B1 (fr)

Also Published As

Publication number Publication date
AR108090A1 (es) 2018-07-18
MA43601B1 (fr) 2020-05-29

Similar Documents

Publication Publication Date Title
PH12018502124B1 (en) Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
PH12021550809A1 (en) Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
ZA202303227B (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
MX2021015408A (es) Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton.
MX386415B (es) Uso de (s)-n-(5-((r)-2-(2,5-difluorofenil) pirrolidin-1-il)- pirazolo [1,5-a] pirimidin-3-il) -3-hidroxipirrolidina-1- carboxamida para tratar cánceres pediátricos.
MX382255B (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA43601A1 (fr) Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
JOP20180088B1 (ar) صيغ سائلة من (s)-n-(5-((r)-2-(2، 5-داي فلورو فينيل)-بيروليدين-1-يل)-بيرازولو[1، 5-a] بيريميدين-3-يل)-3-هيدروكسي بيروليدين-1-كربوكساميد
MA57504B1 (fr) Forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
TH1801006190A (th) สารประกอบสำหรับการผลิตสูตรผสมที่เป็นของเหลวสำหรับการรักษามะเร็งในเด็ก
JOP20180089A1 (ar) طرق علاج سرطانات الأطفال